Effect of COX-2 inhibitor lumiracoxib and the TNF-alpha antagonist etanercept on TNBS-induced colitis in Wistar rats

Effect of COX-2 inhibitor lumiracoxib and the TNF-alpha antagonist etanercept on TNBS-induced colitis in Wistar rats

Autor Ribeiro Paiotti, Ana Paula Autor UNIFESP Google Scholar
Ribeiro, Daniel Araki Autor UNIFESP Google Scholar
Silva, Roseane Mendes Autor UNIFESP Google Scholar
Marchi, Patricia Autor UNIFESP Google Scholar
Oshima, Celina Tizuko Fujiyama Autor UNIFESP Google Scholar
Artigiani Neto, Ricardo Autor UNIFESP Google Scholar
Miszputen, Sender Jankiel Autor UNIFESP Google Scholar
Franco, Marcello Autor UNIFESP Google Scholar
Instituição Universidade Federal de São Paulo (UNIFESP)
Resumo Crohn's disease (CD) is associated with gut barrier dysfunction. Besides the baseline barrier defect, a subgroup of patients also expresses an intestinal barrier hyperresponsiveness to nonsteroidal anti-inflammatory drugs. On the other hand, the anti-tumour necrosis factor alpha (TNF-alpha) treatment has brought benefits to these patients. Thus, this study aimed to evaluate the effect of lumiracoxib, a selective-cyclooxygenase-2 (COX-2) inhibitor, and Etanercept (ETC), a TNF-alpha antagonist on the 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced experimental colitis. A total of 47 Wistar rats were randomized into seven groups, as follows: (1) Sham: sham induced-colitis; (2) TNBS: nontreated induced-colitis; (3) Lumiracoxib control; (4) Lumiracoxib-treated induced-colitis; (5) ETC control; (6) ETC-treated induced-colitis; (7) Lumiracoxib-ETC-treated induced-colitis. Rats from groups 6 and 7 presented significant improvement of macroscopic and histopathological damages in the distal colon. the gene expression of COX-2 mRNA, as well of TNF-alpha mRNA, decreased significantly in groups 6 and 7 compared to the TNBS nontreated and lumiracoxib-treated groups. the treatment only with lumiracoxib did not reduce the inflammation on TNBS-induced experimental colitis. ETC attenuated the damage seen in the colon and reduced the inflammation caused by TNBS. Our results suggest that down-regulation of TNF-alpha and COX-2 resulted in a decrease in inflammation caused by TNBS and thus provided some protection from the colonic damage caused by TNBS.
Assunto Inflammatory bowel disease
TNBS-colitis
TNF-alpha
Cyclooxygenase-2
Lumiracoxib
Etanercept
Idioma Inglês
Financiador Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
Data 2012-06-01
Publicado em Journal of Molecular Histology. Dordrecht: Springer, v. 43, n. 3, p. 307-317, 2012.
ISSN 1567-2379 (Sherpa/Romeo, fator de impacto)
Editor Springer
Extensão 307-317
Fonte http://dx.doi.org/10.1007/s10735-012-9400-8
Direito de acesso Acesso restrito
Tipo Artigo
Web of Science WOS:000307288800007
URI http://repositorio.unifesp.br/handle/11600/34942

Mostrar registro completo




Arquivos deste item

Arquivos Tamanho Formato Visualização

Não existem arquivos associados a este item.

Este item aparece na(s) seguinte(s) coleção(s)